Taken altogether, these results further suggest that the CD4+ T cell activation was indeed vaccine-dependent and that using HOCl-treated tumor lysates as antigen source for therapeutic vaccination purposes leads to a stimulation of the CD4+ T cell compartment, at least in adjuvant settings in ovarian cancer patients. This evidence concerns the gene CD4 and neoplasm.